Lepta 250mg Tablets 70s

Doctors prescribe it alongside capecitabine or letrozole for patients who have progressed on prior HER2 targeted treatment.

Lepta 250mg Tablets Ingredients and Usage

Lepta 250mg Tablets contain lapatinib, a dual tyrosine kinase inhibitor belonging to the targeted anticancer drug class. Doctors prescribe it combined with capecitabine for HER2 positive advanced or metastatic breast cancer in patients who have already received an anthracycline, a taxane, and trastuzumab.

Lepta 250mg Tablets are also combined with letrozole for postmenopausal women with hormone receptor positive, HER2 positive metastatic breast cancer where hormonal therapy is appropriate. Treatment must follow disease progression on trastuzumab and continue under specialist oncology supervision.

How Does Lepta 250mg Tablets Work?

Lapatinib blocks the tyrosine kinase activity of both HER2 and epidermal growth factor receptor, two proteins that drive uncontrolled growth in HER2 positive breast cancer cells. It binds reversibly to the intracellular kinase domain of both receptors.

By blocking signaling through HER2 and EGFR, Lepta 250mg Tablets interrupt the downstream pathways that promote tumor cell proliferation and survival. This dual blockade allows it to remain active even in cancer cells that have developed some resistance to trastuzumab.

Lepta 250mg Tablets Side Effects

Lepta 250mg Tablets commonly cause digestive and skin related side effects, often alongside the chemotherapy or hormone therapy given with it.

• Diarrhea, which can become severe if not managed promptly

• Nausea and vomiting

• Skin rash

• Loss of appetite

• Fatigue

• Nail disorders

• Nosebleeds

Warnings

• Lepta 250mg Tablets carry a boxed warning for hepatotoxicity; severe liver injury and fatal outcomes have been reported, so liver function must be monitored before and during treatment.

• The medicine can reduce left ventricular ejection fraction and lead to congestive heart failure; cardiac function should be assessed before starting treatment and monitored periodically.

• Severe diarrhea can progress to dehydration and kidney failure if untreated; report frequent or severe diarrhea to a doctor promptly and stay well hydrated.

• Lepta 250mg Tablets can rarely cause interstitial lung disease or pneumonitis; seek care for new cough or shortness of breath.

• Avoid use in pregnancy; effective contraception is required during treatment and for at least one week after the last dose.

• Avoid breastfeeding during treatment and for at least five days after the last dose.

• Lepta 250mg Tablets are extensively metabolized by CYP3A4; avoid combining with strong CYP3A4 inhibitors or inducers, and use caution with grapefruit products.

Lepta 250mg Tablets Storage Conditions

Store Lepta 250mg Tablets at room temperature, away from direct sunlight, heat, and moisture. Keep tablets in their original packaging until the dose is due. Store this medicine out of reach of children and dispose of any expired or unused tablets according to local guidelines for cytotoxic agents.